Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non–Small-Cell Lung Carcinoma
-
Published:2003-02-15
Issue:4
Volume:21
Page:624-630
-
ISSN:0732-183X
-
Container-title:Journal of Clinical Oncology
-
language:en
-
Short-container-title:JCO
Author:
Salgia Ravi1, Lynch Thomas1, Skarin Arthur1, Lucca Joan1, Lynch Cathleen1, Jung Ken1, Hodi F. Stephen1, Jaklitsch Michael1, Mentzer Steve1, Swanson Scott1, Lukanich Jean1, Bueno Raphael1, Wain John1, Mathisen Douglas1, Wright Cameron1, Fidias Panos1, Donahue Dean1, Clift Shirley1, Hardy Steve1, Neuberg Donna1, Mulligan Richard1, Webb Iain1, Sugarbaker David1, Mihm Martin1, Dranoff Glenn1
Affiliation:
1. From the Departments of Adult Oncology, Surgery, and Biostatistics, Dana-Farber Cancer Institute; Departments of Adult Oncology and Surgery, Brigham and Women’s Hospital; Departments of Adult Oncology, Surgery, Biostatistics, Genetics, Pathology, and Medicine, Division of Hematology-Oncology, and Children’s Hospital, Harvard Medical School; Departments of Surgery, Medicine, and Pathology, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA; and Cell Genesys, Foster City, CA.
Abstract
Purpose: We demonstrated that vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates potent, specific, and long-lasting antitumor immunity in multiple murine models and patients with metastatic melanoma. To test whether this vaccination strategy enhances antitumor immunity in patients with metastatic non–small-cell lung cancer (NSCLC), we conducted a phase I clinical trial.Patients and Methods: Resected metastases were processed to single-cell suspension, infected with a replication-defective adenoviral vector encoding GM-CSF, irradiated, and cryopreserved. Individual vaccines consisted of 1 × 106, 4 × 106, or 1 × 107cells, depending on overall yield, and were administered intradermally and subcutaneously at weekly and biweekly intervals.Results: Vaccines were successfully manufactured for 34 (97%) of 35 patients. The average GM-CSF secretion was 513 ng/106cells/24 h. Toxicities were restricted to grade 1 to 2 local skin reactions. Nine patients were withdrawn early because of rapid disease progression. Vaccination elicited dendritic cell, macrophage, granulocyte, and lymphocyte infiltrates in 18 of 25 assessable patients. Immunization stimulated the development of delayed-type hypersensitivity reactions to irradiated, dissociated, autologous, nontransfected tumor cells in 18 of 22 patients. Metastatic lesions resected after vaccination showed T lymphocyte and plasma cell infiltrates with tumor necrosis in three of six patients. Two patients surgically rendered as having no evidence of disease at enrollment remain free of disease at 43 and 42 months. Five patients showed stable disease durations of 33, 19, 12, 10, and 3 months. One mixed response was observed.Conclusion: Vaccination with irradiated autologous NSCLC cells engineered to secrete GM-CSF enhances antitumor immunity in some patients with metastatic NSCLC.
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Cited by
259 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|